prof. MUDr. Mgr. Marek Mráz, Ph.D.
Research Group Leader Senior, Marek Mráz Research Group
Office: bldg. E35/216
Kamenice 753/5
625 00 Brno
Phone: | +420 549 49 8143 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 267
2024
-
Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status
Blood advances, year: 2024, volume: 8, edition: 13, DOI
-
Computational Design of Pore-Forming Peptides with Potent Antimicrobial and Anticancer Activities
Journal of Medicinal Chemistry, year: 2024, volume: 67, edition: 16, DOI
-
FoxO1 signaling in B cell malignancies and its therapeutic targeting.
FEBS Letters, year: 2024, DOI
-
FoxO1/Rictor axis induces a non-genetic adaptation to Ibrutinib via Akt activation in chronic lymphocytic leukemia
The Journal of Clinical Investigation, year: 2024, DOI
-
Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drug
Leukemia, year: 2024, volume: 38, edition: 8, DOI
2023
-
5′-UTR mRNA splicing determines CD20 levels
Year: 2023, type: Article in Periodical (without peer review)
-
Coculture model with CD40L, IL4 and IL21 for study chronic lymphocytic leukemia proliferation.
Year: 2023, type: Conference abstract
-
FOX01-rictor AXIS induces AKT phosporylation during CLL cell adaptation to BCR inhibitors: Implications for combinatorial therapy.
Year: 2023, type: Conference abstract
-
FOXO1-RICTOR AXIS induces adaptive increase in AKT activity during BCR inhibitor therapy in CLL: Implications for combination therapy.
Year: 2023, type: Conference abstract
-
Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia.
Year: 2023, type: Conference abstract